Market cap
$5,724 Mln
Revenue (TTM)
$7,683 Mln
P/E Ratio
12.2
P/B Ratio
0.9
Div. Yield
2.1 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
0.1 %
-
ROCE
-- %
-
Industry P/E
26.31
-
EV/EBITDA
8.8
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$0.6
-
Face value
--
-
Shares outstanding
680,575,312
10 Years Aggregate
CFO
€6,327.82 Mln
EBITDA
€11,809.86 Mln
Net Profit
€4,583.81 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Grifols S.A. - ADR
| -13.8 | -2.1 | -12.3 | 11.6 | 2.7 | -14.8 | -6.0 |
|
BSE Sensex*
| -8.6 | 3.8 | -7.4 | -4.1 | 8.2 | 9.5 | 11.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Grifols S.A. - ADR
| 25.7 | -35.4 | 36.0 | -24.3 | -37.5 | -19.9 | 29.2 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Grifols S.A. - ADR
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma,... Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain. Address: Parque Empresarial Can Sant Joan, Barcelona, Spain, 08174 Read more
-
Executive Chairman
Mr. Thomas H. Glanzmann
-
Executive Chairman
Mr. Thomas H. Glanzmann
-
Headquarters
Barcelona
-
Website
FAQs for Grifols S.A. - ADR
What is the current share price of Grifols SA - ADR Today?
The share price of Grifols SA - ADR is $8.06 (NASDAQ) as of 07-May-2026 16:00 EDT. Grifols SA - ADR has given a return of 2.7% in the last 3 years.
What is the current PB & PE ratio of Grifols SA - ADR?
The P/E ratio of Grifols SA - ADR is 12.19 times as on 07-May-2026, a 54 discount to its peers’ median range of 26.31 times.
The P/B ratio of Grifols SA - ADR is 0.91 times as on 07-May-2026, a 84 discount to its peers’ median range of 5.84 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
16.48
|
1.21
|
|
2024
|
32.26
|
0.86
|
|
2023
|
185.51
|
1.46
|
|
2022
|
31.20
|
1.02
|
|
2021
|
--
|
--
|
What is the 52 Week High and Low of Grifols SA - ADR?
The 52-week high and low of Grifols SA - ADR are Rs 11.14 and Rs 7.09 as of 08-May-2026.
What is the market cap of Grifols SA - ADR?
Grifols SA - ADR has a market capitalisation of $ 5,724 Mln as on 07-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Grifols SA - ADR?
Before investing in Grifols SA - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.